Combined use of pramipexole and sertraline for the treatment of depression

Patent 6255329 Issued on July 3, 2001. Estimated Expiration Date:

July 6, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
Patent #: 4536518
Issued on: 08/20/1985
Inventor: Welch, Jr. , et al.

Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
Patent #: 4843086
Issued on: 06/27/1989
Inventor: Griss, deceased , et al.

Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals
Patent #: 4886812
Issued on: 12/12/1989
Inventor: Griss, deceased, et al.

Method of treating anxiety-related disorders using sertraline
Patent #: 4962128
Issued on: 10/09/1990
Inventor: Doogan, et al.

Sertraline polymorph
Patent #: 5248699
Issued on: 09/28/1993
Inventor: Sysko, et al.

Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity Patent #: 6191153
Issued on: 02/20/2001
Inventor: Hammer, et al.

Inventor

Maj, Jerzy

Assignee

Boehringer Ingelheim GmbH

Application

No. 348591 filed on 07/06/1999

US Classes:

514/367, Bicyclo ring system having the thiazole ring as one of the cyclos514/647Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings

Examiners

Primary: Rose, Shep K.

Attorney, Agent or Firm

Raymond; R.P., Witkowski; T. X., Stempel; A. R.

International Classes

A61K 031/425
A61K 031/135

Foreign Application Priority Data

1998-07-07 DE

Abstract

The present invention relates to the use of 2-amino-4,5,6,7-tetrahydro-6-n-propylamino-benzothiazole (pramipexole), the (+)- or (-)- enantiomer thereof, or one of the pharmacologically acceptable salts thereof, in conjunction with sertraline for the improved treatment of depression and depressive states.

Other References

Maj et al Eur. J. Pharmacol. 324(1):31-37 Pra Antipsychotic & Sulpiride, 1997.
Ferrari et al Psychopharmacology(Berlin) 113(2):172-176 Pra & Sulpiride, 1993.
Carter et al Eur. J. Pharmacol. 200(1):65-72 Pra & Sulpiride, 1991.
Borsini et al Psychopharmacology (Berlin) 97(2):183-188 Forced Swimming Test Discovers Antidepressant Activity, 1989.
Piercey et al Clinical Neuropharmacology 18 Suppl. 1 534-542 Pra & Quinpirole, 1995.
Willner Psycyhopharmacology 83(1):1-16 Learned Helplessness Test for Antidepress, 1984.
Borsini et al Psychopharmacology 94(2):147-160 FST in Rats, not Mice Detects Antidepressants, 1988.
Skrebuhhova et al Methods & Findings Exp. Clin. Pharmacol. 21(3):173-178 FST 4, 1999.
Harkin et al Eur. J. Pharmacol. 364 2-3 123-132 Sertraline FST, Jan. 1999.
J. Maj, Z. Rogoz, G. Skuza & K. Kolodziejczyk; "Antidepressant Effects Of Pramipexole, A Novel Dopamine Receptor Agonist"; Journal of Neural Transmission; Aug. 6, 1997; pp. 525-533; vol. 104; Pub. Springer-Verlag; Austria
J. Maj, Z. Rogoz, G. Skuza & K. Kolodziejczyk; "Pramipexole Given Repeatedly Increases Responsiveness Of Dopamine D2 and D3 Receptors"; Abstrac--XIIIth International Congress Of Pharmacology; Jul. 26-31, 1998; Poster Topic p. 35; Germany
O. Benkert, G. Gruender & H. Wetzel; "Dopamine Autoreceptor Agonists In The Treatment of Schizophrenia and Major Depression*"; Review--Pharmacopsychiatry; Nov. 1992; Review pp. 254-260; Georg Thieme Verlag Stuttgart; German